(S)-N-((8-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine | 1201630-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-N-((8-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine
• CAS: 1201630-36-5
• 化学式: C₁₈H₁₉BrN₄
• 分子量: 371.28
• InChiKey: VVHVUHCPCFAXJH-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  23.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.43
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 (S)-N-((8-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 反应 12.0h， 以27%的产率得到(8S)-N-methyl-N-[[8-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyridin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine
  参考文献：
  名称：

  Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1

  摘要：

  Synthesis of several novel imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV are described. Synthetic approaches allowing for variation of the substitution pattern are outlined and resulting changes in antiviral activity and pharmacokinetics are highlighted. Several compounds with low nanomolar anti-HIV activity and oral bioavailability are described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.056
• 作为产物：
  描述：

  (S)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine 、 8-溴-咪唑并[1,2-a]吡啶-2-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 15.0h， 以89%的产率得到(S)-N-((8-bromoimidazo[1,2-a]pyridin-2-yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine
  参考文献：
  名称：

  Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1

  摘要：

  Synthesis of several novel imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV are described. Synthetic approaches allowing for variation of the substitution pattern are outlined and resulting changes in antiviral activity and pharmacokinetics are highlighted. Several compounds with low nanomolar anti-HIV activity and oral bioavailability are described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.056